Format

Send to

Choose Destination
Blood. 2019 May 9;133(19):2027-2030. doi: 10.1182/blood-2018-11-852491. Epub 2019 Feb 25.

Fostamatinib for the treatment of chronic immune thrombocytopenia.

Author information

1
Hematology Division, Brigham and Women's Hospital, Boston, MA; and.
2
Harvard Medical School, Boston, MA.

Abstract

Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib's mechanism of action and its clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center